Cargando…

The Effect of Genotyping on the Number of Pharmacotherapeutic Gene–Drug Interventions in Chronic Kidney Disease Patients

Patients with chronic kidney disease (CKD) stage 3–5 are polypharmacy patients. Many of these drugs are metabolized by cytochrome P450 (CYP450) and CYP450. Genetic polymorphism is well known to result in altered drug metabolism capacity. This study determined the added value of pharmacogenetic testi...

Descripción completa

Detalles Bibliográficos
Autores principales: Kerskes, Catharina H. M., van den Eijnde, Carien J. M. E., Aarnoudse, Albert-Jan L. H. J., Grouls, René J. E., Deiman, Birgit A. L. M., Deenen, Maarten J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10145606/
https://www.ncbi.nlm.nih.gov/pubmed/37104075
http://dx.doi.org/10.3390/pharmacy11020069
_version_ 1785034376849915904
author Kerskes, Catharina H. M.
van den Eijnde, Carien J. M. E.
Aarnoudse, Albert-Jan L. H. J.
Grouls, René J. E.
Deiman, Birgit A. L. M.
Deenen, Maarten J.
author_facet Kerskes, Catharina H. M.
van den Eijnde, Carien J. M. E.
Aarnoudse, Albert-Jan L. H. J.
Grouls, René J. E.
Deiman, Birgit A. L. M.
Deenen, Maarten J.
author_sort Kerskes, Catharina H. M.
collection PubMed
description Patients with chronic kidney disease (CKD) stage 3–5 are polypharmacy patients. Many of these drugs are metabolized by cytochrome P450 (CYP450) and CYP450. Genetic polymorphism is well known to result in altered drug metabolism capacity. This study determined the added value of pharmacogenetic testing to the routine medication evaluation in polypharmacy patients with CKD. In adult outpatient polypharmacy patients with CKD3-5 disease, a pharmacogenetic profile was determined. Then, automated medication surveillance for gene–drug interactions was performed based on the pharmacogenetic profile and the patients’ current prescriptions. Of all identified gene–drug interactions, the hospital pharmacist and the treating nephrologist together assessed clinical relevance and necessity of a pharmacotherapeutic intervention. The primary endpoint of the study was the total number of applied pharmacotherapeutic interventions based on a relevant gene–drug interaction. A total of 61 patients were enrolled in the study. Medication surveillance resulted in a total of 66 gene–drug interactions, of which 26 (39%) were considered clinically relevant. This resulted in 26 applied pharmacotherapeutic interventions in 20 patients. Systematic pharmacogenetic testing enables pharmacotherapeutic interventions based on relevant gene–drug interactions. This study showed that pharmacogenetic testing adds to routine medication evaluation and could lead to optimized pharmacotherapy in CKD patients.
format Online
Article
Text
id pubmed-10145606
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-101456062023-04-29 The Effect of Genotyping on the Number of Pharmacotherapeutic Gene–Drug Interventions in Chronic Kidney Disease Patients Kerskes, Catharina H. M. van den Eijnde, Carien J. M. E. Aarnoudse, Albert-Jan L. H. J. Grouls, René J. E. Deiman, Birgit A. L. M. Deenen, Maarten J. Pharmacy (Basel) Article Patients with chronic kidney disease (CKD) stage 3–5 are polypharmacy patients. Many of these drugs are metabolized by cytochrome P450 (CYP450) and CYP450. Genetic polymorphism is well known to result in altered drug metabolism capacity. This study determined the added value of pharmacogenetic testing to the routine medication evaluation in polypharmacy patients with CKD. In adult outpatient polypharmacy patients with CKD3-5 disease, a pharmacogenetic profile was determined. Then, automated medication surveillance for gene–drug interactions was performed based on the pharmacogenetic profile and the patients’ current prescriptions. Of all identified gene–drug interactions, the hospital pharmacist and the treating nephrologist together assessed clinical relevance and necessity of a pharmacotherapeutic intervention. The primary endpoint of the study was the total number of applied pharmacotherapeutic interventions based on a relevant gene–drug interaction. A total of 61 patients were enrolled in the study. Medication surveillance resulted in a total of 66 gene–drug interactions, of which 26 (39%) were considered clinically relevant. This resulted in 26 applied pharmacotherapeutic interventions in 20 patients. Systematic pharmacogenetic testing enables pharmacotherapeutic interventions based on relevant gene–drug interactions. This study showed that pharmacogenetic testing adds to routine medication evaluation and could lead to optimized pharmacotherapy in CKD patients. MDPI 2023-04-04 /pmc/articles/PMC10145606/ /pubmed/37104075 http://dx.doi.org/10.3390/pharmacy11020069 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Kerskes, Catharina H. M.
van den Eijnde, Carien J. M. E.
Aarnoudse, Albert-Jan L. H. J.
Grouls, René J. E.
Deiman, Birgit A. L. M.
Deenen, Maarten J.
The Effect of Genotyping on the Number of Pharmacotherapeutic Gene–Drug Interventions in Chronic Kidney Disease Patients
title The Effect of Genotyping on the Number of Pharmacotherapeutic Gene–Drug Interventions in Chronic Kidney Disease Patients
title_full The Effect of Genotyping on the Number of Pharmacotherapeutic Gene–Drug Interventions in Chronic Kidney Disease Patients
title_fullStr The Effect of Genotyping on the Number of Pharmacotherapeutic Gene–Drug Interventions in Chronic Kidney Disease Patients
title_full_unstemmed The Effect of Genotyping on the Number of Pharmacotherapeutic Gene–Drug Interventions in Chronic Kidney Disease Patients
title_short The Effect of Genotyping on the Number of Pharmacotherapeutic Gene–Drug Interventions in Chronic Kidney Disease Patients
title_sort effect of genotyping on the number of pharmacotherapeutic gene–drug interventions in chronic kidney disease patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10145606/
https://www.ncbi.nlm.nih.gov/pubmed/37104075
http://dx.doi.org/10.3390/pharmacy11020069
work_keys_str_mv AT kerskescatharinahm theeffectofgenotypingonthenumberofpharmacotherapeuticgenedruginterventionsinchronickidneydiseasepatients
AT vandeneijndecarienjme theeffectofgenotypingonthenumberofpharmacotherapeuticgenedruginterventionsinchronickidneydiseasepatients
AT aarnoudsealbertjanlhj theeffectofgenotypingonthenumberofpharmacotherapeuticgenedruginterventionsinchronickidneydiseasepatients
AT groulsreneje theeffectofgenotypingonthenumberofpharmacotherapeuticgenedruginterventionsinchronickidneydiseasepatients
AT deimanbirgitalm theeffectofgenotypingonthenumberofpharmacotherapeuticgenedruginterventionsinchronickidneydiseasepatients
AT deenenmaartenj theeffectofgenotypingonthenumberofpharmacotherapeuticgenedruginterventionsinchronickidneydiseasepatients
AT kerskescatharinahm effectofgenotypingonthenumberofpharmacotherapeuticgenedruginterventionsinchronickidneydiseasepatients
AT vandeneijndecarienjme effectofgenotypingonthenumberofpharmacotherapeuticgenedruginterventionsinchronickidneydiseasepatients
AT aarnoudsealbertjanlhj effectofgenotypingonthenumberofpharmacotherapeuticgenedruginterventionsinchronickidneydiseasepatients
AT groulsreneje effectofgenotypingonthenumberofpharmacotherapeuticgenedruginterventionsinchronickidneydiseasepatients
AT deimanbirgitalm effectofgenotypingonthenumberofpharmacotherapeuticgenedruginterventionsinchronickidneydiseasepatients
AT deenenmaartenj effectofgenotypingonthenumberofpharmacotherapeuticgenedruginterventionsinchronickidneydiseasepatients